Table 1.
Baseline patient characteristics
| Characteristic | Genotype | |||||||
|---|---|---|---|---|---|---|---|---|
| Mutant BRAF
|
Wild type*
|
|||||||
| All (n=36)
|
V600E (n=18)
|
Non-V600E (n=18)
|
(n=257)
|
|||||
| No. | % | No. | % | No. | % | No. | % | |
| Median age -- yrs | 62 | 63 | 61 | 62 | ||||
| Range | (41-94) | (50-94) | (41-78) | (26-87) | ||||
| Gender -- no. (%) | ||||||||
| Male | 17 | 47 | 8 | 44 | 9 | 50 | 128 | 50 |
| Female | 19 | 53 | 10 | 56 | 9 | 50 | 129 | 50 |
| Race -- no. (%) | ||||||||
| White, non-Hispanic | 34 | 94 | 16 | 88 | 18 | 100 | 222 | 86 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 6 |
| Black | 1 | 3 | 1 | 6 | 0 | 0 | 16 | 6 |
| White, Hispanic | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 |
| Unknown | 1 | 3 | 1 | 6 | 0 | 0 | 1 | <1 |
| Smoking history -- no. (%)† | ||||||||
| Never-smoker | 7 | 19 | 5 | 28 | 2 | 11 | 56 | 22 |
| ≤ 10 pack-years | 4 | 11 | 1 | 6 | 3 | 17 | 29 | 11 |
| > 10 pack-years | 25 | 69 | 12 | 67 | 13 | 72 | 171 | 67 |
| Histology -- no. (%) | ||||||||
| Adenocarcinoma | 34 | 94 | 17 | 94 | 17 | 94 | 222 | 87 |
| Adenosquamous | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 |
| Squamous | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 2 |
| LCNEC | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 |
| NSCLC NOS | 2 | 6 | 1 | 6 | 1 | 6 | 21 | 8 |
| Stage‡ -- no. (%) | ||||||||
| I | 4 | 11 | 2 | 11 | 2 | 11 | 34 | 13 |
| II | 1 | 3 | 1 | 6 | 0 | 0 | 17 | 7 |
| III | 6 | 17 | 2 | 11 | 4 | 22 | 66 | 26 |
| IV | 25 | 69 | 13 | 72 | 12 | 67 | 140 | 54 |
*
Wild type at all predefined exons of BRAF, EGFR, KRAS and no ALK rearrangement
†
Data not available for one patient in the wild type cohort
‡
Stage at initial NSCLC diagnosis, AJCC staging system 7th edition
Abbreviations: LCNEC, large cell neuroendocrine carcinoma; NOS, not otherwise specified